Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mussie Akalu"'
Autor:
Caroline H. Williams-Gray, Diane Stephenson, Klaus Romero, Judith Anton, Ferdous Gheyas, Nathan J. Hanan, Jonas Weidemann, Minhua Yang, Malidi Ahamadi, Massimo Bani, Bob Stafford, Charles S. Venuto, Chao Chen, Vincent Thuillier, Ka Lai Yee, Gennaro Pagano, Monica Javidnia, Sreeraj Macha, Nitin Mehrotra, Vikram Sinha, Kenneth Marek, Yaming Hang, Hans Smit, Anne Pedata, Mussie Akalu, Babak Boroojerdi, David T. Dexter, Glenn T. Stebbins
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:508-518
Leucine-rich repeat kinase 2 (LRRK2) inhibitors are currently in clinical development as interventions to slow progression of Parkinson's disease (PD). Understanding the rate of progression in PD as measured by both motor and non-motor features is pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9053473f0a3b3a25461e5d893d23049
https://doi.org/10.1002/cpt.2277
https://doi.org/10.1002/cpt.2277
Autor:
Romeo Maciuca, Rachael A Lawson, Timothy Nicholas, David T. Dexter, Malidi Ahamadi, Chao Chen, David J. Burn, Kenneth Marek, Minhua Yang, Klaus Romero, Bob Stafford, Sreeraj Macha, Julie A. Stone, Diane Stephenson, Jackson Burton, Daniela J. Conrado, Vikram Sinha, Hans Smit, Massimo Bani, Mussie Akalu, Jill Gallagher, Babak Boroojerdi, Jonas Weidemann, Charles S. Venuto
Publikováno v:
Clin Pharmacol Ther
A quantitative assessment of Parkinson’s disease (PD) progression is critical for optimizing clinical trials design. Disease progression model was developed using pooled data from the Progression Marker Initiative study and the Incidence of Cogniti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2390c3bcdfe2ede372186277a46746bb
https://doi.org/10.1002/cpt.1634
https://doi.org/10.1002/cpt.1634